GTC Biotherapeutics (fka GTCB)

[dodah_2]

Yep... in respect to other indications for Atryn such as AD, burn therapy, DIC, DVT, etc., is it correct to say the essential product that's being produced will be unchanged for all indications except for dosing and means of application? If that's true, then wouldn't the entire body of testing results be available for FDA applications? If so, would the FDA require the same level of testing for each indication that it would for an unknown drug? Tia.